The In Vivo CRO Market is expected to register a CAGR of 8% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report on the in vivo contract research organization (CRO) market is segmented by service type into preclinical services, clinical trial services, and others. Applications analyzed include drug development, toxicology testing, and others. End-users include pharmaceutical companies, biotechnology firms, and academic & research institutions. The regional analysis covers key markets such as North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses.
Purpose of the ReportThe report In Vivo CRO Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
In Vivo CRO Market Segmentation
Specimen Type- Rodent
- Non-Rodent
- Non GLP
- GLP
- Autoimmune/Inflammatory Conditions
- Pain Management
- Oncology
- CNS Conditions
- Diabetes
- Obesity
- Other Indications
Strategic Insights
In Vivo CRO Market Growth Drivers- Increasing Demand for Drug Discovery and Development: Benefits from rising new and far more effective therapies, it remains had the allegiance of the in vivo contract research organization (CRO) market. The provision of in vivo CRO services pertaining to animal testing, PK studies, and toxicity assessments have added immense value to preclinical drug discovery and development. There is increasing industry pressure on the global pharmaceutical industry for new drugs to address an increasing tapestry of therapeutic indications including oncology, cardiovascular diseases, and autoimmune disorders. According to PhRMA, there are currently more than 7,000 new drugs in the development pipeline, indicating an increasing demand for preclinical research services. Thereafter, the increased demands stand positioned to set in vivo CROs in demand, hence hastening the whole drug development process and aligning it with regulatory requirements and safety.
- Advancement of Biotechnology and Personalized Medicine: The biotechnology and personalized medicine spheres are also important drivers of request for specialized in vivo CRO services. As the biotechnology industry advances further, it will also create the possibility for in vivo testing for the efficacy and safety of biologics, gene therapies, and cell-based therapies. Personalized medicine itself is also pushing for more refined and well-established preclinical studies to help tailor treatments according to someone's genetic makeup. Because of the intricate and immensely sophisticated therapies available, in vivo CROs come in handy to carry out preclinical studies on such therapies as they see them performing in living organisms; thus, it strongly augurs well for the market's growth.
- Cost-Effectiveness and Time Efficiency: Pharmaceutical and biotechnology companies stand to save big on costs and time by outsourcing in vivo studies to specialized contract research organizations. In particular, the services offered by in vivo CROs very greatly reduce the need for companies to develop their own facilities, personnel, and equipment. This outsourcing model also accelerates the development timelines, as CROs have the resources and experience to conduct studies faster and more efficiently. With the global drug development process becoming increasingly complex and expensive, the ability to reduce operational costs and enhance productivity is a significant driver for the growth of the in vivo CRO market.
- Adoption of 3D and organ-on-a-chip models in the CRL industry: One of the most significant trends in in vivo CRO markets is the greater adoption of advanced models such as 3D cell cultures and organ-on-a-chip systems. Such innovative approaches facilitate considerably vivid insights into drug interactions, toxicity, and efficacy when compared to conventional analogs. Organ-on-a-chip devices make it possible for organs and tissues to act like human ones so researchers can observe real-time responses to drugs in a controlled environment. This trend paves the way for more predictive and ethical models that replicate human biology well enough to eliminate the need for animal testing in some fields.
- The increased focus on non-rodent models: Standard rodent models (e.g., rats and mice) have commonly been used over the years in in vivo studies; however, there is a significant shift towards using non-rodent models, including non-human primates, rabbits, and pigs. Non-rodent models are frequently preferred because they closely mimic humans in terms of physiology features and are majorly advanced in the studies on drug metabolism and toxicity. The requirement arises from the need for better-quality data for clinical trials and submissions to regulatory bodies. The use of non-rodent models is rising in areas where western medicine depends on significant therapeutic practices like oncology and immunology, aiming to study the possibilities of human responses to drug activities while studying their effects on clinical setups.
- Application of AI in preclinical research: AI is already transforming how in vivo studies are conducted, offering the possibility of linking disparate data sources and creating vast databases of biological information in preclinical research. More specially, it could provide the proper algorithms for dealing with the datasets produced from in vivo experiments. AI is becoming more prevalent to facilitate the analysis of complex datasets this way, provide vital and insight into speedily identifying potential drug candidates, and predict outcomes accurately. The AI-enabled tools can also help optimize study design and reducing animal usage, and enhancing the reproducibility of results. As the integration of AI in research workflows continues to evolve, it is expected to streamline drug development processes, offering more precise insights and accelerating the time to market for new therapies.
- Expanding Biopharmaceutical and Gene Therapy Markets: The biopharmaceutical sector, particularly the growing market for gene therapies, offers significant opportunities for in vivo CROs. the drug will perform in clinical settings, leading to improved trial success rates. One area of rapid advancement is that of in vivo gene therapy testing. Gene therapies that modify a patient's gene to prevent or treat diseases require complex in vivo work to evaluate the safety and efficacy endpoints. Gene therapy is rapidly becoming a go-to in the treatment of rare and genetic diseases; hence, the need for specialized in vivo test services skyrockets because of it. In vivo CROs with expertise in gene therapy are poised to benefit from the growing biopharmaceutical market as they provide tailored services for gene therapy developers.
- Regulatory Pressure for Safer, More Effective Drugs: With expanding regulatory requirements for the drug approval process, in vivo CROs can help pharmaceutical companies by navigating the increasingly rigid safety and efficacy standards. Regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) continue to encourage essential preclinical testing—particularly in the areas of safety, immunotoxicity, and drug interactions. In vivo CROs will play a considerable role in assisting companies with these regulatory obstacles before advancing a drug candidate to human clinical trials. Tightening regulatory regimes will unfailingly increase demand for in vivo services that help ensure compliance with global standards.
- Increasing Demand for Customized In Vivo Models: The shift toward personalized medicine and targeted therapeutics is an offer to in vivo CROs for custom testing models. Pharmaceutical companies increasingly seek in vivo models that mirror human conditions and reflect patient-specific features. The CROs providing personalized or patient-derived models, such as patient-derived xenograft (PDX) models, are gaining a competitive advantage. These tailored models allow researchers to make better predictions on how patients will respond to the drugs in clinical settings, subsequently increasing success rates.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the In Vivo CRO Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the In Vivo CRO Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The In Vivo CRO Market is expected to register a CAGR of 8% from 2025-2031.
The major driving factors supporting the In Vivo CRO Market growth are- Increasing demand for drug discovery and development, advancement of biotechnology and personalized medicine, and cost-effectiveness and time efficiency are key factors driving the in vivo CRO market.
Key Future Trends in the In Vivo CRO Market are- Adoption of 3D and organ-on-a-chip models in the CRL industry, the increased focus on non-rodent models, and the application of AI in preclinical research are driving advancements in the in vivo CRO market.
Key companies in the In Vivo CRO Market are - American Preclinical Services, LLC., Charles River, Covance Inc., GVK Biosciences Private Limited, Iris Pharma, MELIOR DISCOVERY, Pronexus Analytical AB, Syneos Health, Washington Biotechnology, Inc., WuXi AppTec
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 In Vivo CRO Market - By Specimen Type
1.3.2 In Vivo CRO Market - By Study Type
1.3.3 In Vivo CRO Market - By Indication
1.3.4 In Vivo CRO Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. IN VIVO CRO MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. IN VIVO CRO MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. IN VIVO CRO MARKET - GLOBAL MARKET ANALYSIS
6.1. IN VIVO CRO - GLOBAL MARKET OVERVIEW
6.2. IN VIVO CRO - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. IN VIVO CRO MARKET - REVENUE AND FORECASTS TO 2028 - SPECIMEN TYPE
7.1. OVERVIEW
7.2. SPECIMEN TYPE MARKET FORECASTS AND ANALYSIS
7.3. RODENT
7.3.1. Overview
7.3.2. Rodent Market Forecast and Analysis
7.3.3. Rats Market
7.3.3.1. Overview
7.3.3.2. Rats Market Forecast and Analysis
7.3.4. Mice Market
7.3.4.1. Overview
7.3.4.2. Mice Market Forecast and Analysis
7.3.5. Other Rodents Market
7.3.5.1. Overview
7.3.5.2. Other Rodents Market Forecast and Analysis
7.4. NON-RODENT
7.4.1. Overview
7.4.2. Non-Rodent Market Forecast and Analysis
7.4.3. Hamsters Market
7.4.3.1. Overview
7.4.3.2. Hamsters Market Forecast and Analysis
7.4.4. Guinea Pigs Market
7.4.4.1. Overview
7.4.4.2. Guinea Pigs Market Forecast and Analysis
7.4.5. Gerbils Market
7.4.5.1. Overview
7.4.5.2. Gerbils Market Forecast and Analysis
7.4.6. Other Non-Rodents Market
7.4.6.1. Overview
7.4.6.2. Other Non-Rodents Market Forecast and Analysis
8. IN VIVO CRO MARKET - REVENUE AND FORECASTS TO 2028 - STUDY TYPE
8.1. OVERVIEW
8.2. STUDY TYPE MARKET FORECASTS AND ANALYSIS
8.3. NON GLP
8.3.1. Overview
8.3.2. Non GLP Market Forecast and Analysis
8.3.3. In House Market
8.3.3.1. Overview
8.3.3.2. In House Market Forecast and Analysis
8.3.4. Outsourcing Market
8.3.4.1. Overview
8.3.4.2. Outsourcing Market Forecast and Analysis
8.4. GLP
8.4.1. Overview
8.4.2. GLP Market Forecast and Analysis
8.4.3. In House Market
8.4.3.1. Overview
8.4.3.2. In House Market Forecast and Analysis
8.4.4. Outsourcing Market
8.4.4.1. Overview
8.4.4.2. Outsourcing Market Forecast and Analysis
9. IN VIVO CRO MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
9.1. OVERVIEW
9.2. INDICATION MARKET FORECASTS AND ANALYSIS
9.3. AUTOIMMUNE/ INFLAMMATORY CONDITIONS
9.3.1. Overview
9.3.2. Autoimmune/ Inflammatory Conditions Market Forecast and Analysis
9.4. PAIN MANAGEMENT
9.4.1. Overview
9.4.2. Pain Management Market Forecast and Analysis
9.5. ONCOLOGY
9.5.1. Overview
9.5.2. Oncology Market Forecast and Analysis
9.6. CNS CONDITIONS
9.6.1. Overview
9.6.2. CNS Conditions Market Forecast and Analysis
9.7. DIABETES
9.7.1. Overview
9.7.2. Diabetes Market Forecast and Analysis
9.8. OBESITY
9.8.1. Overview
9.8.2. Obesity Market Forecast and Analysis
9.9. OTHER INDICATIONS
9.9.1. Overview
9.9.2. Other Indications Market Forecast and Analysis
10. IN VIVO CRO MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America In Vivo CRO Market Overview
10.1.2 North America In Vivo CRO Market Forecasts and Analysis
10.1.3 North America In Vivo CRO Market Forecasts and Analysis - By Specimen Type
10.1.4 North America In Vivo CRO Market Forecasts and Analysis - By Study Type
10.1.5 North America In Vivo CRO Market Forecasts and Analysis - By Indication
10.1.6 North America In Vivo CRO Market Forecasts and Analysis - By Countries
10.1.6.1 United States In Vivo CRO Market
10.1.6.1.1 United States In Vivo CRO Market by Specimen Type
10.1.6.1.2 United States In Vivo CRO Market by Study Type
10.1.6.1.3 United States In Vivo CRO Market by Indication
10.1.6.2 Canada In Vivo CRO Market
10.1.6.2.1 Canada In Vivo CRO Market by Specimen Type
10.1.6.2.2 Canada In Vivo CRO Market by Study Type
10.1.6.2.3 Canada In Vivo CRO Market by Indication
10.1.6.3 Mexico In Vivo CRO Market
10.1.6.3.1 Mexico In Vivo CRO Market by Specimen Type
10.1.6.3.2 Mexico In Vivo CRO Market by Study Type
10.1.6.3.3 Mexico In Vivo CRO Market by Indication
10.2. EUROPE
10.2.1 Europe In Vivo CRO Market Overview
10.2.2 Europe In Vivo CRO Market Forecasts and Analysis
10.2.3 Europe In Vivo CRO Market Forecasts and Analysis - By Specimen Type
10.2.4 Europe In Vivo CRO Market Forecasts and Analysis - By Study Type
10.2.5 Europe In Vivo CRO Market Forecasts and Analysis - By Indication
10.2.6 Europe In Vivo CRO Market Forecasts and Analysis - By Countries
10.2.6.1 Germany In Vivo CRO Market
10.2.6.1.1 Germany In Vivo CRO Market by Specimen Type
10.2.6.1.2 Germany In Vivo CRO Market by Study Type
10.2.6.1.3 Germany In Vivo CRO Market by Indication
10.2.6.2 France In Vivo CRO Market
10.2.6.2.1 France In Vivo CRO Market by Specimen Type
10.2.6.2.2 France In Vivo CRO Market by Study Type
10.2.6.2.3 France In Vivo CRO Market by Indication
10.2.6.3 Italy In Vivo CRO Market
10.2.6.3.1 Italy In Vivo CRO Market by Specimen Type
10.2.6.3.2 Italy In Vivo CRO Market by Study Type
10.2.6.3.3 Italy In Vivo CRO Market by Indication
10.2.6.4 Spain In Vivo CRO Market
10.2.6.4.1 Spain In Vivo CRO Market by Specimen Type
10.2.6.4.2 Spain In Vivo CRO Market by Study Type
10.2.6.4.3 Spain In Vivo CRO Market by Indication
10.2.6.5 United Kingdom In Vivo CRO Market
10.2.6.5.1 United Kingdom In Vivo CRO Market by Specimen Type
10.2.6.5.2 United Kingdom In Vivo CRO Market by Study Type
10.2.6.5.3 United Kingdom In Vivo CRO Market by Indication
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific In Vivo CRO Market Overview
10.3.2 Asia-Pacific In Vivo CRO Market Forecasts and Analysis
10.3.3 Asia-Pacific In Vivo CRO Market Forecasts and Analysis - By Specimen Type
10.3.4 Asia-Pacific In Vivo CRO Market Forecasts and Analysis - By Study Type
10.3.5 Asia-Pacific In Vivo CRO Market Forecasts and Analysis - By Indication
10.3.6 Asia-Pacific In Vivo CRO Market Forecasts and Analysis - By Countries
10.3.6.1 Australia In Vivo CRO Market
10.3.6.1.1 Australia In Vivo CRO Market by Specimen Type
10.3.6.1.2 Australia In Vivo CRO Market by Study Type
10.3.6.1.3 Australia In Vivo CRO Market by Indication
10.3.6.2 China In Vivo CRO Market
10.3.6.2.1 China In Vivo CRO Market by Specimen Type
10.3.6.2.2 China In Vivo CRO Market by Study Type
10.3.6.2.3 China In Vivo CRO Market by Indication
10.3.6.3 India In Vivo CRO Market
10.3.6.3.1 India In Vivo CRO Market by Specimen Type
10.3.6.3.2 India In Vivo CRO Market by Study Type
10.3.6.3.3 India In Vivo CRO Market by Indication
10.3.6.4 Japan In Vivo CRO Market
10.3.6.4.1 Japan In Vivo CRO Market by Specimen Type
10.3.6.4.2 Japan In Vivo CRO Market by Study Type
10.3.6.4.3 Japan In Vivo CRO Market by Indication
10.3.6.5 South Korea In Vivo CRO Market
10.3.6.5.1 South Korea In Vivo CRO Market by Specimen Type
10.3.6.5.2 South Korea In Vivo CRO Market by Study Type
10.3.6.5.3 South Korea In Vivo CRO Market by Indication
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa In Vivo CRO Market Overview
10.4.2 Middle East and Africa In Vivo CRO Market Forecasts and Analysis
10.4.3 Middle East and Africa In Vivo CRO Market Forecasts and Analysis - By Specimen Type
10.4.4 Middle East and Africa In Vivo CRO Market Forecasts and Analysis - By Study Type
10.4.5 Middle East and Africa In Vivo CRO Market Forecasts and Analysis - By Indication
10.4.6 Middle East and Africa In Vivo CRO Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa In Vivo CRO Market
10.4.6.1.1 South Africa In Vivo CRO Market by Specimen Type
10.4.6.1.2 South Africa In Vivo CRO Market by Study Type
10.4.6.1.3 South Africa In Vivo CRO Market by Indication
10.4.6.2 Saudi Arabia In Vivo CRO Market
10.4.6.2.1 Saudi Arabia In Vivo CRO Market by Specimen Type
10.4.6.2.2 Saudi Arabia In Vivo CRO Market by Study Type
10.4.6.2.3 Saudi Arabia In Vivo CRO Market by Indication
10.4.6.3 U.A.E In Vivo CRO Market
10.4.6.3.1 U.A.E In Vivo CRO Market by Specimen Type
10.4.6.3.2 U.A.E In Vivo CRO Market by Study Type
10.4.6.3.3 U.A.E In Vivo CRO Market by Indication
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America In Vivo CRO Market Overview
10.5.2 South and Central America In Vivo CRO Market Forecasts and Analysis
10.5.3 South and Central America In Vivo CRO Market Forecasts and Analysis - By Specimen Type
10.5.4 South and Central America In Vivo CRO Market Forecasts and Analysis - By Study Type
10.5.5 South and Central America In Vivo CRO Market Forecasts and Analysis - By Indication
10.5.6 South and Central America In Vivo CRO Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil In Vivo CRO Market
10.5.6.1.1 Brazil In Vivo CRO Market by Specimen Type
10.5.6.1.2 Brazil In Vivo CRO Market by Study Type
10.5.6.1.3 Brazil In Vivo CRO Market by Indication
10.5.6.2 Argentina In Vivo CRO Market
10.5.6.2.1 Argentina In Vivo CRO Market by Specimen Type
10.5.6.2.2 Argentina In Vivo CRO Market by Study Type
10.5.6.2.3 Argentina In Vivo CRO Market by Indication
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. IN VIVO CRO MARKET, KEY COMPANY PROFILES
12.1. AMERICAN PRECLINICAL SERVICES, LLC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CHARLES RIVER
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. COVANCE INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. GVK BIOSCIENCES PRIVATE LIMITED
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. IRIS PHARMA
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MELIOR DISCOVERY
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. PRONEXUS ANALYTICAL AB
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SYNEOS HEALTH
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. WASHINGTON BIOTECHNOLOGY, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. WUXI APPTEC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. American Preclinical Services, LLC.
2. Charles River
3. Covance Inc.
4. GVK Biosciences Private Limited
5. Iris Pharma
6. MELIOR DISCOVERY
7. Pronexus Analytical AB
8. Syneos Health
9. Washington Biotechnology, Inc.
10. WuXi AppTec
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For